Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.
about
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenProtective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination.Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study.Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence.Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients.Speed of onset of bronchodilator response to salbutamol inhaled via different devices in asthmatics: a bioassay based on functional antagonism.Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma.Identification of factors involved in medication compliance: incorrect inhaler technique of asthma treatment leads to poor compliance.New approaches to managing asthma: a US perspectiveThe effects of daily bathing on symptoms of patients with bronchial asthmaComparison and optimal use of fixed combinations in the management of COPD.The effects of long-acting β2-agonists plus inhaled corticosteroids for early reversibility in patients with airway obstruction.Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma.Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroid.Is it time for single-inhaler asthma therapy?Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids.Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma.Real-world effects of two inhaled corticosteroid/long-acting β₂-agonist combinations in the treatment of asthma.
P2860
Q24235303-41408171-1D4B-4B7B-8EFF-7D4E81FE8AFBQ33934063-02E8F465-AE43-4D5C-865D-46D438DA0DB9Q34470553-85C8812C-2410-4120-B59E-191F08220E4FQ34573003-29AA3541-3711-4A08-9C33-A8FFC71B4AC7Q34623797-D55EBA75-7709-4DFF-83FC-B2467260594FQ35039844-FC2A73A3-BC78-4ABE-9F06-75419AFD5555Q35827812-74743D4A-DF2C-4A8A-945F-E5007F11483FQ36326508-3173BE2E-649C-4F4D-BC5C-BE46F7AA988DQ36581576-AF2B52FF-9DA9-489C-A98E-F0013CBB9F92Q36823534-737C5056-3216-4CCD-9EF2-4F55460CB8C0Q36850157-D29E1133-AD9C-4AF9-9F40-62220C355FA8Q37017520-1A188954-4B72-471C-85D1-F724D372076BQ37127990-D29E7811-7ABF-4DE8-9203-987EA115B592Q37362634-58F8C0A5-FFC5-47A7-AB30-CFAE0B95E11DQ37556546-BDC525A6-ADA2-41E7-98A5-EF0BC309C2C1Q39290816-D58CCDC6-F50A-4942-A98F-7A51330E01A2Q39374605-C2637F90-D4EC-452D-BC68-20CDCB5CE675Q42110251-1A6EA352-C082-413F-8C0A-5BD08361BEEBQ42984977-3C4B3C11-8632-494D-92E9-72C153D22F6CQ46619161-A83141C0-F6D1-4A22-9912-77E89A70FCEBQ53229520-762CD8FB-F279-42A6-843E-3E80C94B4177Q53593298-042F2990-EE54-491B-88E4-F86C57BA9F20
P2860
Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@ast
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@en
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@nl
type
label
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@ast
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@en
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@nl
prefLabel
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@ast
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@en
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@nl
P2093
P1476
Budesonide/formoterol in a sin ...... to-severe bronchoconstriction.
@en
P2093
Hanneke J van der Woude
Martin Boorsma
Peter B F Bergqvist
René Aalbers
Trea H Winter
P356
10.1016/J.PUPT.2003.11.001
P577
2004-01-01T00:00:00Z